A carregar...

Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain

Erlotinib and gefitinib, tyrosine kinase inhibitors used to block EGFR (epidermal growth factor receptor) signalling in cancer, are thought to bind only the active conformation of the EGFR-TKD (tyrosine kinase domain). Through parallel computational and crystallographic studies, we show in the prese...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Park, Jin H., Liu, Yingting, Lemmon, Mark A., Radhakrishnan, Ravi
Formato: Artigo
Idioma:Inglês
Publicado em: Portland Press Ltd. 2012
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3507260/
https://ncbi.nlm.nih.gov/pubmed/23101586
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1042/BJ20121513
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!